J&J Imposes Claims-Data Reporting Requirement on 340B Providers, Threatening Discount Suspension
核心洞察
Johnson & Johnson now requires all 340B providers to submit pharmacy or medical claims data for each dispensed drug to receive point-of-sale discounts.
Providers failing to submit documentation within 45 days could have all their 340B discounts suspended, forfeiting savings of 20% to 50%.
Hospital groups argue drugmakers lack statutory authority to impose reporting requirements and have urged federal regulators to intervene.
Johnson & Johnson has begun requiring hospitals and medical clinics to submit detailed claims data for every drug dispensed or administered under the 340B federal discount program, the latest escalation in a widening conflict between drugmakers and providers over the decades-old program.
The policy took effect Tuesday and applies to all 340B providers, including hospitals and community health centers, with the exception of those in HIV/AIDS (搜索) programs. Under the requirement, providers must submit extensive pharmacy or medical claims data each time one of the drugmaker's products is dispensed through 340B if they want those drugs discounted at the point of sale.
For most drugs, providers have up to 45 days to submit documentation, such as when the prescription was filled at a pharmacy and the identification numbers for prescribing providers. J&J says the data allows it to confirm that a drug is actually eligible for 340B and that it does not overlap with discounts through other programs like Medicaid.
Suspension Threat and Provider Pushback
If providers fail to comply, J&J could suspend their access to all 340B discounts, the drugmaker said. The consequence is significant: hospitals would lose out on the 20% to 50% savings they receive on 340B drugs.
J&J framed the change as a program-integrity measure. "We have determined that collection of limited, commercially standard 340B claims data in accordance with this policy is necessary to identify and address 340B-related transactions that involve prohibited duplicate discounts and diversion," J&J wrote in a Sept. 4 notice to providers announcing the change. "Without access to this data, [J&J] cannot effectively identify these prohibited transactions and tailor its program integrity activities to promote efficient oversight and dispute resolution."
Providers reject that rationale. Hospital groups argue that drugmakers are attempting to avoid paying out discounts that hospitals and clinics are owed under 340B, which was established in the early 1990s to help cash-strapped providers afford pricey prescription drugs. According to hospital lobbies, drugmakers do not have statutory authority to create additional reporting requirements, and the groups have urged federal regulators to intervene.
The Health Resources and Services Administration (搜索), the HHS agency that oversees 340B, has said it is reviewing the policies.
A Growing Manufacturer Trend
J&J is the latest manufacturer to impose a reporting requirement in the program. Eli Lilly began cutting providers out of 340B discounts if they did not submit claims data this summer, sparking condemnation — and at least one lawsuit — from hospitals. Novo Nordisk has also implemented a data-sharing requirement.
The reporting requirements represent one strategy from drugmakers to reshape 340B pricing. In 2024, a cadre of developers, including J&J, said they would instead require hospitals to pay full price for 340B drugs and then distribute savings in the form of rebates later, after verifying that the medications were eligible for 340B. However, no such programs went into effect after federal judges agreed with HRSA and the hospital industry that Congress did not give drugmakers the authority to tweak 340B's payment structure on their own. J&J has sued HHS and HRSA over the issue.
J&J issued an additional notice on Sept. 4 stating that hospitals can only receive 340B pricing at one contract pharmacy within 40 miles of the parent site, also effective Tuesday. That policy kicks in Nov. 3 for grantees.
Program Growth Fuels Scrutiny
Disputes over 340B between hospitals and drugmakers are not new, but the disagreements have increased in scope and intensity in recent years as the program has grown, lending more weight to arguments from pharmaceutical companies, lawmakers and health policy experts that 340B may be spiraling out of control.
In 2025, hospitals and outpatient facilities purchased $100 billion worth of drugs in 340B, up almost 23% from the year prior and more than double the volume in 2021, according to government data. Much of that growth is fueled by hospitals acquiring clinics, contracting with more pharmacies and prescribing higher-cost drugs in order to inflate their discounts in the program, according to the Congressional Budget Office.
Lawmakers have also highlighted issues with 340B, including that the statute does not put any parameters around what providers must do with the savings or require them to report that information.